Policy

With the CDC’s decision to roll back recommendations to vaccinate for several conditions, questions have arisen as to what that may mean in the US.

Almost half of the monthly-updated CDC databases had unexplained pauses in 2025, mostly affecting vaccination data, raising transparency and public health concerns.

A multistakeholder study explores how law enforcement presence in EDs affects survivors of violence and outlines trauma-informed, patient-centered policy solutions.

The CEOs of UnitedHealth Group, CVS Health, Elevance Health, The Cigna Group, and Ascendiun attended hearings in the House of Representatives all day Thursday.

A new bipartisan funding bill funds key departments ahead of the deadline in an effort to avoid another government shutdown.

The decline in primary care providers threatens Medicare FFS patients' access to new visits, highlighting urgent needs for policy reform and workforce solutions.

The ACCESS Model signals a shift toward outcome-aligned payments and a necessary reframing of what “value” actually means.

New York City nurses continue their strike over staffing, safety, and benefits through negotiations on day 5 of the city’s largest nursing strike.

In this week’s health equity news, ICHRAs may offer flexible health coverage options amid ACA subsidy uncertainties, and advocates rally for mental health funding stability.

With ACA subsidies in limbo, ICHRAs may reshape how Americans access coverage. Here are 5 FAQs explaining what they are, who benefits, and key trade-offs.

Trump's Great Healthcare Plan aims to lower drug prices, reduce insurance premiums, and enhance transparency, according to the White House.

The Trump administration says it will restore vital SAMHSA funding after swift advocacy from mental health supporters.

Federal grant terminations by SAMHSA threaten vital mental health and substance use services, risking lives amid rising suicide rates and addiction crises.

The latest dietary guidelines emphasize reducing processed foods, promoting whole foods, and increasing protein intake, aiming to improve public health.

As part of the deal, AbbVie is expanding its direct-to-patient offerings through the TrumpRx program.

ED law enforcement interactions affect survivors of violence and immigrant patients, emphasizing training and advocacy.

Patients undergoing lung or colon cancer surgery at rural hospitals that later closed had better outcomes after transfer to high-performing oncology centers.

W. Kimryn Rathmell, MD, PhD, FASCO, champions the dyad model to enhance oncology care accessibility, bridging gaps between rural patients and clinical trials.

Johnson & Johnson partners with the Trump Administration to lower drug prices and utilize TrumpRx.com, joining a growing list of pharmaceutical companies.

The maternal morbidity was compared between states that passed laws to regulate providers with states that did not.

This week, we look at 5 key health care changes the Trump Administration made in 2025, changes to the immunization schedule, and new research on telehealth accessibility.

President Donald J. Trump's health care overhaul during the first year of his second term reshapes Medicaid, vaccine policies, and drug pricing.

The House voted to extend the insurance subsidies under the Affordable Care Act (ACA), but the bill could face problems in the Senate.

As the CDC shifts childhood vaccines to shared decision-making, new surveys show many Americans misunderstand what the policy means—and who it involves.

The CDC announced a significant change to the childhood immunization schedule that would reduce vaccine recommendations.

AI revolutionizes pharmacy by automating workloads, enhancing patient care, and navigating drug pricing challenges amid evolving federal policies.

Our top 5 obesity articles of 2025 highlight GLP-1 prescribing trends, insurance coverage, co-pay caps, real-world use, and access challenges.

Explore the evolving landscape of drug pricing, reproductive rights, and health policy in 2025, featuring insights on SC pembrolizumab and RFK Jr's hearings.

The most-viewed content focused on the “One Big Beautiful Bill,” the Most Favored Nation drug policy, and other changes under the Trump administration.

Trump secures new pricing deals with 9 drugmakers, advancing his effort to align US drug costs with Europe and expand direct-to-consumer purchasing.